文献速递淋巴瘤

脑脊液中克隆型DNA检测作为淋巴瘤中枢神经系统侵犯标志物

Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

本研究评估基于NGS检测脑脊液中肿瘤源性免疫球蛋白基因重排克隆型DNA的价值。该法在已知中枢侵犯患者的脑脊液样本中100%检出克隆型DNA,包括细胞学和流式阴性者。在新诊断高危B细胞淋巴瘤患者中,脑脊液阳性与12个月内29%的中枢复发风险相关,阴性者为0%(P=.045)。

要点

  • NGS-MRD可在细胞学和流式阴性的脑实质病变患者脑脊液中检出克隆型DNA。
  • 新诊断高危B细胞淋巴瘤中36%患者脑脊液可检出克隆型DNA。
  • 脑脊液阳性者12个月中枢复发累积风险29%,阴性者0%。

核心结论

  • 检测脑脊液中克隆型DNA有助于可疑脑实质复发的诊断,并可能增强新诊断淋巴瘤中枢复发风险评估。

研究设计与样本

  • 研究NGS法检测脑脊液中肿瘤源性克隆型免疫球蛋白基因重排,含诊断评估和前瞻性风险预后观察。

主要发现

  • 13例已知中枢侵犯患者脑脊液样本克隆型DNA检出率100%,含7例仅脑实质病变且细胞学和流式阴性者。
  • 6例历史DNA样本在采集前中位39个月时标准PCR未显示克隆性重排。
  • 22例新诊断高危B细胞淋巴瘤中8例(36%)脑脊液可检出克隆型DNA。
  • 尽管接受鞘内预防,脑脊液阳性者12个月内中枢复发累积风险29%,阴性者0%(P=.045)。

关键数值与推荐

  • 脑脊液阳性者12个月内中枢复发累积风险29%,阴性者0%(P=.045)。
  • 新诊断高危B细胞淋巴瘤脑脊液克隆型DNA检出率36%(8/22)。
  • 已知中枢侵犯者脑脊液克隆型DNA检出率100%(13/13)。

临床怎么用

  • NGS-MRD检测脑脊液克隆型DNA可辅助诊断可疑脑实质复发。
  • 对新诊断高危B细胞淋巴瘤,脑脊液克隆型DNA检测可能帮助筛选可从新型中枢预防获益者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnosis of parenchymal central nervous system (CNS) invasion and prediction of risk for future CNS recurrence are major challenges in the management of aggressive lymphomas, and accurate biomarkers are needed to supplement clinical risk predictors. For this purpose, we studied the results of a next-generation sequencing (NGS)-based assay that detects tumor-derived DNA for clonotypic immunoglobulin gene rearrangements in the cerebrospinal fluid (CSF) of patients with lymphomas. Used as a diagnostic tool, the NGS-minimal residual disease (NGS-MRD) assay detected clonotypic DNA in 100% of CSF samples from 13 patients with known CNS involvement. They included 7 patients with parenchymal brain disease only, whose CSF tested negative by standard cytology and flow cytometry, and 6 historical DNA aliquots collected from patients at a median of 39 months before accession, which had failed to show clonal rearrangements using standard polymerase chain reaction. For risk prognostication, we prospectively collected CSF from 22 patients with newly diagnosed B-cell lymphomas at high clinical risk of CNS recurrence, of whom 8 (36%) had detectable clonotypic DNA in the CSF. Despite intrathecal prophylaxis, a positive assay of CSF was associated with a 29% cumulative risk of CNS recurrence within 12 months of diagnosis, in contrast with a 0% risk among patients with negative CSF (P = .045). These observations suggest that detection of clonotypic DNA can aid in the diagnosis of suspected parenchymal brain recurrence in aggressive lymphoma. Furthermore, the NGS-MRD assay may enhance clinical risk assessment for CNS recurrence among patients with newly diagnosed lymphomas and help select those who may benefit most from novel approaches to CNS-directed prophylaxis.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Olszewski AJ, Chorzalska AD, Petersen M, et al. Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma. Blood Adv. 2021. PMID: 34551072. doi:10.1182/bloodadvances.2021004512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。